AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$ADPT

ROBINS CHAD M sold $14.9M of ADPT

ROBINS CHAD M (CEO and Chairman) sold 600,000 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.80 ($24.48–$25.57, $14.88M total) across 4 trades over 2026-08-17 to 2026-08-18.

Original reporting
SEC EDGAR · ROBINS CHAD M
Published Aug 20, 2026, 12:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishMed
01

Why it matters

The insider sale provides fresh data on insider sentiment, a key factor for short‑term traders.

02

Market read

First‑report insider sale of $15M by the CEO, modestly bearish for ADPT.

03

What to watch

No 10b5‑1 plan and the CEO retains a large stake, suggesting confidence in long-term outlook.

Relevance 7/10Novelty 7/10Timing: filed 2026-08-19 after market

Background

Adaptive Biotechnologies (ADPT) is a biotech firm focused on immune profiling and diagnostics.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

CEO Chad M. Robins sold 600,000 shares for $14.9M, reducing his stake to 2.18M shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

A $15M sale by the CEO signals possible concerns, but no 10b5‑1 plan and holdings remain sizable.

Market effects

Sector

May affect biotech sector sentiment as insider sales are watched closely.

Regional

Limited to US biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider may be diversifying; the sale does not necessarily indicate negative fundamentals.

Key entities

  • Company
    Adaptive Biotechnologies Corp

    Issuer of the Form 4 filing.

  • Individual
    Chad M. Robins

    CEO and Chairman of ADPT.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ADPT insider trading history →

Related articles

JUL 29
$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnolo

SEC EDGAR 8-K6 min
JUN 5
$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.

finance.yahoo.com4 min